n, $3.4 million in non-cash depreciation, amortization, and stock-based compensation expense, $0.9 million in proceeds from the exercise of stock options and $0.1 million of other working capital outflows.
- Vanda's cash, cash equivalents and marketable securities as of June 30, 2009 totaled approximately $29.0 million, compared to approximately $46.5 million as of December 31, 2008.
- Net loss for the second quarter of 2009 was $12.4 million, compared to a net loss of $6.5 million for the first quarter of 2009 and a net loss of $13.5 million for the second quarter of 2008.
- Net loss per common share for the second quarter of 2009 was $0.46, compared to $0.24 for the first quarter of 2009 and $0.51 for the second quarter of 2008.
Based on its current operating plans, Vanda believes that its existing cash, cash equivalents and marketable securities, will be sufficient to meet its anticipated operating needs through 2009. However, given the recent approval by the FDA of the NDA for Fanapt(TM), Vanda is currently evaluating alternative commercial strategies for the product. These strategies include, in addition to Vanda launching Fanapt(TM) on its own, entering into one or more partnerships, other collaboration agreements or strategic transactions that may provide capital to support Vanda's operations.
Vanda has scheduled a conference call for today, Monday, August 10, 2009, at 10:00 AM ET. During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and Stephanie Irish, Acting CFO, will discuss quarterly results and other corporate activities. Investors can call 1-800-599-9829 (domestic) and 1-617-847-8703 (international) prior to the 10:00 AM start time and ask for the Va
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results2
. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference3
. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests4
. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 20085
. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights6
. Vanda Pharmaceuticals Reports Third Quarter 2008 Results7
. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results8
. Vanda Pharmaceuticals Reports First Quarter 2009 Results9
. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting10
. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 200911
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes